Quebec Moves Towards Tighter Benadryl Controls

It seems Quebec is on the verge of making a pretty significant change to how we access certain common medications, specifically those containing diphenhydramine, which includes popular brands like Benadryl. The province is looking to restrict access, pulling these drugs from open pharmacy shelves and placing them behind the counter, requiring a pharmacist's intervention for purchase. This isn't just a random decision; it's a direct response to a troubling surge in poisonings and misuse, and it's got strong backing from key health organizations.

Both the Quebec Poison Centre and the Quebec Order of Pharmacists are firmly supporting this move, and honestly, when you look at the numbers, it's easy to see why. The Poison Centre's statistics paint a rather stark picture: in 2021, they dealt with 549 cases involving diphenhydramine exposure. Fast forward to 2024, and that number jumped to a concerning 603 cases. What's particularly alarming within these figures are the intentional poisonings – rising from 237 to 301 – along with steady numbers of misuse and therapeutic errors. These aren't just minor incidents; they highlight a serious public health challenge.

To put this into perspective, think about Gravol, which contains dimenhydrinate. That medication was moved behind the counter all the way back in 1998, and guess what? Intentional poisoning cases for Gravol are significantly lower, with only 78 recorded in 2024. It suggests that pharmacist oversight truly makes a difference.

Perhaps the most poignant catalyst for this proposed restriction is the tragic death of an 18-year-old in Montérégie in December 2023. This young person succumbed to acute diphenhydramine poisoning, having reportedly purchased the medication from multiple pharmacies. Quebec coroner Vincent Denault, who investigated the case, couldn't quite wrap his head around why a drug with such potential lethality isn't better controlled. It's a sentiment many healthcare professionals share.

So, what exactly would this change entail? Well, moving diphenhydramine-containing medications behind the counter means you'd have to speak with a pharmacist to buy them. The idea isn't to take these medications away entirely, but rather to allow pharmacists to do what they do best: provide supervision, identify potential risks, and spot any concerning purchasing patterns. They would even record each sale in a patient's file, creating a crucial layer of monitoring.

Jean-François Desgagné, who heads the Quebec Order of Pharmacists, put it quite simply, stating, "I think this is the things to do. It's been linked to several deaths over the years." And he's not alone in his concern. Dr. Michael Kalin, a family doctor in Montreal, points out that Benadryl is a first-generation antihistamine known for its sedative side effects, which can be particularly problematic. Think drowsiness, dry eyes, and in older individuals, an increased risk of falls and respiratory issues. Crucially, Dr. Kalin notes that safer, newer alternatives are readily available today.

Even though the goal is safety, there are practical considerations for pharmacies. The Association québécoise des pharmaciens propriétaires (AQPP), for instance, has proposed an amendment to base the behind-the-counter move on specific thresholds, like milligrams per format or number of caplets. This aims to strike a balance between enhancing patient safety and ensuring pharmacy teams can still operate efficiently.

Ultimately, this proposed restriction is currently undergoing a public consultation, meaning the conversation is still very much alive. It’s a vital discussion about balancing easy access to common remedies with the very real dangers of misuse and poisoning, all with an eye on protecting public health.